The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and
cardiovascular diseases, and advances in nuclear medicine imaging procedures.
High demand of nuclear medicines in emerging economies and potential
radiopharmaceuticals in the pipeline create ample opportunities for the nuclear
medicine/radiopharmaceuticals market to grow at a considerable rate in the
coming years.
The advances in neurological applications and
development of new products by the companies are supporting to address the
demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging
procedures are non-invasive and can be used for the treatment of several
diseases, such as cancers, cardiovascular diseases, and neurological disorders.
Request to
Get the Sample Pages at:
The nuclear medicine/radiopharmaceuticals market
is segmented on the basis of type, application, and region. On the basis of
type, the nuclear medicine/radiopharmaceuticals market can be segmented as
diagnostics and therapeutics. The diagnostics segment leads the nuclear
medicine/radiopharmaceuticals market. The diagnostics segment can be further
categorized into single-photon emission computed tomography (SPECT) and
positron emission tomography (PET). SPECT segment will be leading the nuclear
medicine/radiopharmaceutical diagnostics market in the coming years due to its
wider availability and less cost. The therapeutics segment can be further
categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The
beta emitters will be the leading segment in the global nuclear
medicine/radiopharmaceutical therapeutics market.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market
Geographically, North America will be leading the
global nuclear medicine/radiopharmaceuticals market in the coming years due to
increasing prevalence of cancer, ready availability of radiopharmaceuticals,
popularity of nuclear medicine among physicians, and technological
advancements.
Asia-Pacific is the fastest growing region in the
global nuclear medicine/radiopharmaceuticals market. The major reasons for the
fastest growth in the region are increasing healthcare expenditure, and rising
awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan
will be leading the nuclear medicine/radiopharmaceuticals market in
Asia-Pacific region in the coming years.
Some of the major players operating in the global
nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer
Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco
Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced
Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.
